|
|
Post by yash on Apr 5, 2016 8:04:29 GMT -5
|
|
|
|
Post by LosingMyBullishness on Apr 5, 2016 8:06:49 GMT -5
Why not take it from MNKD itself: investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=963557In a nutshell: - Effective today - Sanofi will continue to distribute Afrezza from its existing inventory until MannKind begins to distribute Afrezza during the third quarter. - Information on Marketing, Team in the coming weeks - A positive statement by Steven Edelman on Afrezza - Awareness in diabetes communities raised by Laura Kronen, author of "Too Sweet: The Not-So-Serious Side to Diabetes", diabetes life coach and an early adopter of Afrezza. - MannKind has established an Afrezza Customer Service Center. - Certain Afrezza patient support programs (including co-pay assistance cards) will continue and new programs will be introduced in the second quarter, replacing legacy programs. - Company also plans to present 4 - 6 abstracts at the ADA. |
|
|
|
Post by liane on Apr 5, 2016 8:12:47 GMT -5
Cue the hit pieces; SA already has one up. I won't give them the pleasure of reading it or linking it here.
|
|
|
|
Post by agedhippie on Apr 5, 2016 8:20:55 GMT -5
This line jumped out at me:
According to the agreement as of today Mannkind has the right to take over or duplicate that role. Inferred from that there is no partner immediately to hand, and the pricing will not change since it is Sanofi (or more accurately the JV) insulin that is being sold.
This does not preclude foreign partners, Sanofi can distribute globally, although pricing may be a problem. It seems that in reality we do not get Afrezza back until Q3 given this and the later comment about how long plans will take to be made. The sole change is likely to be marketing but again that seems from the press release to be delayed at least slightly.
|
|
|
|
Post by LosingMyBullishness on Apr 5, 2016 8:27:49 GMT -5
This line jumped out at me: According to the agreement as of today Mannkind has the right to take over or duplicate that role. Inferred from that there is no partner immediately to hand, and the pricing will not change since it is Sanofi (or more accurately the JV) insulin that is being sold. This does not preclude foreign partners, Sanofi can distribute globally, although pricing may be a problem. It seems that in reality we do not get Afrezza back until Q3 given this and the later comment about how long plans will take to be made. The sole change is likely to be marketing but again that seems from the press release to be delayed at least slightly. 'the pricing will not change since it is Sanofi (or more accurately the JV) insulin': If it is JVs insulin than the MNKD would have already received the cash for all of JVs inventory. Did they? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 5, 2016 8:28:51 GMT -5
This line jumped out at me: According to the agreement as of today Mannkind has the right to take over or duplicate that role. Inferred from that there is no partner immediately to hand, and the pricing will not change since it is Sanofi (or more accurately the JV) insulin that is being sold. This does not preclude foreign partners, Sanofi can distribute globally, although pricing may be a problem. It seems that in reality we do not get Afrezza back until Q3 given this and the later comment about how long plans will take to be made. The sole change is likely to be marketing but again that seems from the press release to be delayed at least slightly. Are you sure that when they say "distribute" it is simply Sanofi receiving orders from Rx distributors such as McKesson and shipping to their warehouses around the country? If a foreign partner signed on with Mannkind, they would likely have the task of processing orders, warehousing Afrezza and shipping to distributors who supply pharmacies or if they outsourced this, likely not use a competitor such as Sanofi. |
|
|
|
Post by mike0475 on Apr 5, 2016 8:31:05 GMT -5
until MannKind begins to distribute Afrezza during the third quarter
Does this mean no pricing change to existing inventory? Can MNKD distribute on their own prior to 3q inventory supply reduction?
|
|
|
|
Post by spiro on Apr 5, 2016 8:49:44 GMT -5
Today marks a new beginning in the history of MNKD. “Mankind.” That word should have new meaning for all of us today. We can’t be consumed by our petty differences anymore. We will be united in our common interests. Perhaps it’s fate that today is April 5, and you will once again be fighting against the shorts… Not from tyranny, oppression, or persecution… but from annihilation. We are fighting for our right to financially survive, to live. to exist. And should we win the day, the Fifth of April will no longer be known as an ordinary day, but as the day the longs declared in one voice: We will not go quietly into the night! We will not vanish without a fight! We’re going to live on! We’re going to survive! Today we celebrate our Independence Day from Sanofi!”
Spiro here, just losing money again today, oh well
|
|
|
|
Post by hokiemcd on Apr 5, 2016 8:58:10 GMT -5
Spiro - good variation of one of the greatest movie speeches ever! Now we just need Mannkind to be creative like that and tell us how they will be surviving past this year.
|
|
|
|
Post by peppy on Apr 5, 2016 9:04:50 GMT -5
Today marks a new beginning in the history of MNKD. “Mankind.” That word should have new meaning for all of us today. We can’t be consumed by our petty differences anymore. We will be united in our common interests. Perhaps it’s fate that today is April 5, and you will once again be fighting against the shorts… Not from tyranny, oppression, or persecution… but from annihilation. We are fighting for our right to financially survive, to live. to exist. And should we win the day, the Fifth of April will no longer be known as an ordinary day, but as the day the longs declared in one voice: We will not go quietly into the night! We will not vanish without a fight! We’re going to live on! We’re going to survive! Today we celebrate our Independence Day from Sanofi!” Spiro here, just losing money again today, oh wellmy heart bleeds for you screencast.com/t/gSZUAoRuiABz screencast.com/t/HzmDsMp2
|
|
|
|
Post by brentie on Apr 5, 2016 9:09:04 GMT -5
Today marks a new beginning in the history of MNKD. “Mankind.” That word should have new meaning for all of us today. We can’t be consumed by our petty differences anymore. We will be united in our common interests. Perhaps it’s fate that today is April 5, and you will once again be fighting against the shorts… Not from tyranny, oppression, or persecution… but from annihilation. We are fighting for our right to financially survive, to live. to exist. And should we win the day, the Fifth of April will no longer be known as an ordinary day, but as the day the longs declared in one voice: We will not go quietly into the night! We will not vanish without a fight! We’re going to live on! We’re going to survive! Today we celebrate our Independence Day from Sanofi!” Spiro here, just losing money again today, oh well John, good job. I always look forward to your posts. |
|
|
|
Post by tayl5 on Apr 5, 2016 9:18:16 GMT -5
This line jumped out at me: According to the agreement as of today Mannkind has the right to take over or duplicate that role. Inferred from that there is no partner immediately to hand, and the pricing will not change since it is Sanofi (or more accurately the JV) insulin that is being sold. This does not preclude foreign partners, Sanofi can distribute globally, although pricing may be a problem. It seems that in reality we do not get Afrezza back until Q3 given this and the later comment about how long plans will take to be made. The sole change is likely to be marketing but again that seems from the press release to be delayed at least slightly. As a practical matter, I don't think a new partner would be in any position to do much beyond planning for at least one or two quarters. This is particularly true if MannKind followed the requirements of the agreement with Sanofi and did not engage in substantive negotiations with prospective partners. I don't think anything is precluded but it will also take some time before any new arrangements can be implemented. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 5, 2016 10:13:40 GMT -5
So when do we find out about the settlement?
|
|
|
|
Post by mnholdem on Apr 5, 2016 10:16:03 GMT -5
"Sanofi will continue to distribute Afrezza from its existing inventory until MannKind begins..."
- Read: We will not buy any stock back from Sanofi. They have cost us enough money.
"In the coming weeks, we will roll out more information about our commercial team for Afrezza, the resources that we are designing for patients and physicians, and our plans for the future."
- Read: Sanofi will continue to distribute the Afrezza they bought from us, and which is sitting on pharmacy shelves throughout the U.S., but from this point forward we will handle marketing of Afrezza, thank you very much.
"I am thrilled to work with MannKind to ensure current and new patients know about the continued availability of Afrezza," said Laura Kronen, author of "Too Sweet: The Not-So-Serious Side to Diabetes", diabetes life coach and an early adopter of Afrezza. "To the diabetes community, Afrezza represents advancement in insulin delivery and a novel way to manage their disease."
- Read: We know that building awareness is a critical priority. Sanofi made only a token effort to reach out to the diabetes community. MannKind believes that we can and will reach them, both within and outside the United States, to explain why Afrezza inhalable monomer insulin does, in fact, represent a true advancement in diabetes treatment.
"Today's return of control of Afrezza is a landmark day for MannKind," said Matthew Pfeffer, Chief Executive Officer of MannKind. "We are thrilled to begin the process of making Afrezza the successful mealtime treatment for people with diabetes that we always believed it would be."
- Read: Sanofi's commercial failure should not, in any way, be considered a failure of Afrezza and MannKind intends to prove it.
---
Forward-Looking Statements
"This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind's ability to directly commercialize Afrezza and the commercial potential of Afrezza. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the MannKind's current expectations."
- Read: We choose to omit certain backward-looking statements. Words such as "Sanofi", "incompetence", "sand-bagging", "price barrier", "short-sighted", "conflicts of interest", "control", "failure" and similar expressions are intended to identify backward-looking statements. The word "Sanofi" is intended to indicate a backward-looking company. Now that we have control of Afrezza back from Sanofi, we have something to look forward to again.
Good fortune all.   
|
|
|
|
Post by matt on Apr 5, 2016 10:46:27 GMT -5
This line jumped out at me: This does not preclude foreign partners, Sanofi can distribute globally, although pricing may be a problem. It seems that in reality we do not get Afrezza back until Q3 given this and the later comment about how long plans will take to be made. The sole change is likely to be marketing but again that seems from the press release to be delayed at least slightly. As a practical matter, drugs packaged and LABELLED for the US market generally cannot be sold abroad due to lack of foreign registration and lack of compliance with foreign label rules. For example, even though Sanofi might hold salable inventory they cannot sell it off in France due to lack of a French language package insert and no EMA approval. The red tape required to get compliant simply isn't worth the effort in most cases. |
|
